$40.55 Million in Sales Expected for OraSure Technologies (OSUR) This Quarter

Wall Street brokerages expect that OraSure Technologies (NASDAQ:OSUR) will announce sales of $40.55 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for OraSure Technologies’ earnings. The lowest sales estimate is $40.50 million and the highest is $40.59 million. OraSure Technologies posted sales of $32.55 million during the same quarter last year, which suggests a positive year-over-year growth rate of 24.6%. The firm is scheduled to announce its next earnings results on Wednesday, May 2nd.

On average, analysts expect that OraSure Technologies will report full-year sales of $40.55 million for the current financial year, with estimates ranging from $179.22 million to $182.00 million. For the next fiscal year, analysts expect that the company will post sales of $198.03 million per share, with estimates ranging from $195.06 million to $201.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover OraSure Technologies.

How to Become a New Pot Stock Millionaire

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. The firm had revenue of $52.00 million during the quarter, compared to analysts’ expectations of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. OraSure Technologies’s revenue was up 46.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.13 earnings per share.

Several equities analysts recently issued reports on OSUR shares. BidaskClub raised OraSure Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. ValuEngine raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a report on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. OraSure Technologies currently has a consensus rating of “Buy” and a consensus target price of $22.25.

Shares of OSUR stock opened at $16.72 on Monday. The firm has a market cap of $1,028.18, a P/E ratio of 32.78, a PEG ratio of 4.95 and a beta of 1.65. OraSure Technologies has a 1 year low of $12.02 and a 1 year high of $23.01.

In other news, EVP Brian Smith sold 20,000 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $17.97, for a total value of $359,400.00. Following the completion of the transaction, the executive vice president now directly owns 28,075 shares of the company’s stock, valued at $504,507.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Stephen S. Phd Tang sold 23,333 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the transaction, the director now directly owns 59,749 shares of the company’s stock, valued at $1,073,689.53. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OSUR. Elkfork Partners LLC acquired a new position in OraSure Technologies in the fourth quarter valued at $143,000. Oppenheimer Asset Management Inc. acquired a new position in OraSure Technologies in the third quarter valued at $186,000. Shikiar Asset Management Inc. acquired a new position in OraSure Technologies in the fourth quarter valued at $207,000. AMP Capital Investors Ltd acquired a new position in OraSure Technologies in the fourth quarter valued at $294,000. Finally, Quadrant Private Wealth Management LLC acquired a new position in OraSure Technologies in the fourth quarter valued at $300,000. 93.67% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3342275/40-55-million-in-sales-expected-for-orasure-technologies-osur-this-quarter.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

BMO Capital Markets Cuts Africa Oil  Price Target to C$2.20
BMO Capital Markets Cuts Africa Oil Price Target to C$2.20
Baytex Energy  Given New C$4.50 Price Target at Raymond James
Baytex Energy Given New C$4.50 Price Target at Raymond James
Canadian National Railway  Given New C$107.00 Price Target at Royal Bank of Canada
Canadian National Railway Given New C$107.00 Price Target at Royal Bank of Canada
Enbridge  Price Target Lowered to C$53.00 at Scotiabank
Enbridge Price Target Lowered to C$53.00 at Scotiabank
COPYTRACK Price Tops $0.21 on Major Exchanges
COPYTRACK Price Tops $0.21 on Major Exchanges
Quantstamp  Price Up 30% This Week
Quantstamp Price Up 30% This Week


© 2006-2018 Ticker Report. Google+.